Abstract
The absence of a graft-versus-malignancy (GVM) effect may be responsible for the higher relapse rate seen after autologous hematopoietic cell transplantation (auto-HCT) compared with allogeneic hematopoietic cell transplantation (allo-HCT). Acute GVHD developing after allo-HCT, however, is associated with significant morbidity and mortality. An autoimmune syndrome similar to acute GVHD has been reported to occur after auto-HCT and has been termed the ‘auto-aggression’ syndrome or autologous GVHD (auto-GVHD). Auto-GVHD tends to be milder than classical GVHD, most commonly involves the skin (rarely the gastrointestinal tract, liver or both) and often is self-limited. Auto-GVHD has been reported to occur both spontaneously and in subjects receiving post transplant immune modulation with CsA, IFN-γ or the combination. The development of auto-GVHD depends upon the derangement of self tolerance either through administration of post transplant CsA, depletion of regulatory T cells following the preparative chemoradiotherapy or both. Self-reactive CD8+ T cells paradoxically are able to recognize a self peptide antigen presented by MHC class II molecules and appear to mediate the syndrome. Many clinical trials have been performed using CsA with or without IFN-γ in an attempt to induce auto-GVHD. While many patients do indeed develop the syndrome, any associated anti-tumor effect remains questionable to date. New strategies to exploit auto-GVHD and enhance a GVM effect such as through the depletion of regulatory T cells or through use of newer immunomodulatory agents may improve the efficacy of auto-HCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED . Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.
Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813.
Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413.
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.
Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW . Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745–750.
Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754–757.
Holmberg L, Kikuchi K, Gooley TA, Adams KM, Hockenbery DM, Flowers ME et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12: 226–234.
Saunders MD, Shulman HM, Murakami CS, Chauncey TR, Bensinger WL, McDonald GB . Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004–1008.
Sica S, Chiusolo P, Salutari P, Piccirillo N, Laurenti L, Sora F et al. Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 2000; 9: 375–379.
Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G et al. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol 2000; 111: 745–753.
Glazier A, Tutschka PJ, Farmer ER, Santos GW . Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1–8.
Hess AD, Horwitz L, Beschorner WE, Santos GW . Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718–730.
Jenkins MK, Schwartz RH, Pardoll DM . Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655–1658.
Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J . Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988; 336: 176–179.
Miura Y, Ueda M, Takami A, Shiobara S, Nakao S, Hess AD . Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells. Bone Marrow Transplant 2003; 32: 785–790.
Hess AD . Autologous graft-versus-host disease. J Hematother Stem Cell Res 2000; 9: 297.
Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667–673.
Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478–484.
Park J, Lee MH, Lee HR, Park SH, Lee SH, Lee KE et al. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia. Bone Marrow Transplant 2003; 32: 889–895.
Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R et al. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. Bone Marrow Transplant 1999; 24: 637–640.
Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031–3035.
Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249–257.
Rappeport J, Mihm M, Reinherz E, Lopansri S, Parkman R . Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet 1979; 8145: 717–720.
Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos GW, Hess AD . Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165–1171.
Bryson JS, Lake-Bullock H, Pflugh DL, Jennings CD, Stuart PM, Caywood BE et al. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease. Transplantation 1995; 60: 171–178.
Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ . Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203–2209.
Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK . Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1994; 153: 400–411.
Ruvolo P, Bright E, Kennedy MJ, Morris L, Fischer A, Vogelsang G et al. Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T-cell receptor repertoire. Transplant Proc 1995; 27: 1363–1365.
Miura Y, Thoburn CJ, Bright EC, Sommer M, Lefell S, Ueda M et al. Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD. Blood 2001; 98: 868–876.
Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI . Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000; 95: 3011–3019.
de Arriba F, Corral J, Ayala F, Heras I, Moraleda JM, Osma MM et al. Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. Bone Marrow Transplant 1999; 23: 621–624.
Carella AM, Gaozza E, Congiu A, Carlier P, Frassoni F, Valbonesi M et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Ann Hematol 1991; 62: 156–159.
Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Santos GW . Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leuk Lymphoma 1993; 11: 215–220.
Gaspari AA, Cheng SF, DiPersio JF, Rowe JM . Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. J Am Acad Dermatol 1995; 33: 711–717.
Redman BG, Chou TH, Zalupski M, Uberti J, Flaherty L, Dan M et al. Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with cancer: attempt to induce autologous graft-versus-host reaction to elicit an antitumor response. J Immunother Emphasis Tumor Immunol 1995; 18: 115–118.
Nakamura H, Nakao T, Ujiie H, Karasuno T, Teshima H, Komatsu K et al. Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. J Allergy Clin Immunol 1999; 103: S457–S461.
van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer 2000; 83: 1405–1411.
Miura Y, Ueda M, Zeng W, Wang H, Takani A, Yamazaki H et al. Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: analysis of factors affecting induction. J Allergy Clin Immunol 2000; 106: S51–S57.
Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA . Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation. Bone Marrow Transplant 2004; 33: 1131–1135.
Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD . Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1992; 1: 75–84.
Greiner J, Schmitt M, Li L, Giannopoulos K, Schmitt A, Dohner K et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109–4117.
Zenz T, Ritgen M, Dreger P, Krober A, Barth TF, Schlenk R et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 108: 2127–2130.
Ohsuga Y, Rowe JM, Liesveld J, Burns RP, Gaspari AA . Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant. J Am Acad Dermatol 2000; 43: 437–441.
Hess AD, Thoburn CJ . Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells. Biol Blood Marrow Transplant 2006; 12: 518–529.
Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061.
Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN . Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200: 771–782.
Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623–3633.
Nemunaitis J . Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005; 4: 259–274.
Messina G, Quartarone E, Console G, Cuzzola M, Iacopino O, Martino M et al. Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation. Haematologica 2002; 87: ECR22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kline, J., Subbiah, S., Lazarus, H. et al. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant 41, 505–513 (2008). https://doi.org/10.1038/sj.bmt.1705931
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705931
Keywords
This article is cited by
-
Selective involution of thymic medulla by cyclosporine A with a decrease of mature thymic epithelia, XCR1+ dendritic cells, and epithelium-free areas containing Foxp3+ thymic regulatory T cells
Histochemistry and Cell Biology (2021)
-
Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?
Bone Marrow Transplantation (2017)
-
Engraftment syndrome: double-edged sword of hematopoietic cell transplants
Bone Marrow Transplantation (2015)
-
Autologous GVHD?
Bone Marrow Transplantation (2014)
-
Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma
International Journal of Hematology (2011)